Triflusal: An antiplatelet drug with a neuroprotective effect?

Cardiovascular Drug Reviews

Volumn 24, Issue 1, 2006, Pages 11-24

  González Correa, José Antonio ^a   De La Cruz, José Pedro ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Neuroprotection; Platelets; Stroke; Triflusal

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLIC AMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; NITRIC OXIDE; THROMBOXANE; TRIFLUSAL; NEUROPROTECTIVE AGENT; SALICYLIC ACID DERIVATIVE;

ANEMIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN TISSUE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TRANSFORMATION; DYSPEPSIA; EXPERIMENTAL STUDY; FIBRINOLYSIS; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; IC 50; LOW DRUG DOSE; MEDIATOR; MONOTHERAPY; NEUROPROTECTION; NONHUMAN; PEPTIC ULCER; PHARMACODYNAMICS; PRIMARY PREVENTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STROKE; THROMBOGENESIS; ANIMAL; BIOAVAILABILITY; CEREBROVASCULAR ACCIDENT; FEMALE; MALE; TISSUE DISTRIBUTION;

ANIMALS; BIOLOGICAL AVAILABILITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; FEMALE; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PLATELET AGGREGATION INHIBITORS; SALICYLATES; TISSUE DISTRIBUTION;

EID: 34247853343     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2006.00011.x     Document Type: Review

References (60)

1. Acarín L, González B, Castellano B. Decrease of proinflammatory molecules correlates with neuroprotective effect of the fluorinated salicylate triflusal alter postnatal excitotoxic damage. Stroke 2002 33 : 2499 2505.
2. Acarín L, González B, Castellano B. Oral administration of the anti-inflammatory substance triflusal results in the downregulation of constitutive transcription factor NF-ÊB in the postnatal rat brain. Neurosci Lett 2000 288 : 41 44.
3. Acarín L, González B, Castellano B. Triflusal posttreatment inhibits glial nuclear factor ÊB, downregulates the glial response, and is neuroprotective in an excitotoxic injury in postnatal brain. Stroke 2001 32 : 2394 2402.
4. Adams H, Adams R, Del Zoppo G, Goldstein LB. Guidelines for the early management of patients with ischemic stroke. 2005 update. A scientific statement from the Stroke Council of the American Heart Association/([a-z])merican Stroke Association. Stroke 2005 36 : 916 921.
5. Albors M, Castellarnau C, Vila L, Sola J, Rutllant M. Inhibition of thromboxane production and platelet function by triflusal in healthy volunteers. Rev Farmacol Clin Exp 1987 4 : 11 16.
6. Alvarez Sabin J, Calvo G, Morros R. Secondary prevention of ischemic strokes: effect of dosage of aspirin. Rev Neurol 1997 25 : 541 544.
7. Antiplatelets Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelets therapy. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994 308 : 81 106.
8. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002 324 : 71 86.
9. Aramendi JI, Mestres CA, Martinez-Leon J, Campos V, Munoz G, Navas C. Triflusal vs. oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (TRAC): Prospective, randomized, co-operative trial. Eur J Cardiothorac Surg 2005 27 : 54 60.
10. Bayón Y, Alonso A, Sánchez Crespo, M. 4-trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor κB activation. Br J Pharmacol 1999 126 : 1359 1366.
11. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (Caprie). Lancet 1996 348 : 1329 1339.
12. Castellarnau C, Sáncho MJ, Vila L, Albors M, Rutllant M. Effects and interaction studies of triflusal and other salicylic derivatives on cyclooxygenase in rats. Prostaglandin Leukotrienes Essential Fatty Acids 1988 31 : 83 89.
13. Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev 2005 3 : CD004296.
14. Cruz-Fernandez JM, Lopez-Bescos L, Garcia-Dorado D, et al. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J 2000 21 : 457 465.
15. Culebras A, Rotta-Escalante R, Vila J, et al. TAPIRSS investigadors. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. Neurology 2004 62 : 1073 1080.
16. De La Cruz JP, Pavía J, Bellido I, González, MC, Sánchez de la Cuesta, F. Platelet antiaggregatory effects of triflusal in human whole blood. Meth Find Exp Clin Pharmacol 1988 10 : 273 277.
17. De La Cruz JP, Pavía J, Bellido, I, Sánchez de la Cuesta, F. Effect of triflusal and acetylsalicylic acid on platelet aggregation in human whole blood: Influence of red blood cells and leukocytes. Meth Find Exp Clin Pharmacol 1988 10 : 363 367.
18. De La Cruz JP, Pavía J, García-Arnés, J, Sánchez de la Cuesta, F. Effects of triflusal and acetylsalicylic acid on platelet aggregation in whole blood of diabetic patients. Eur J Haematol 1988 40 : 232 236.
19. De La Cruz JP, Villalobos MA, Garcia PJ, Smith-Agreda, JM, Sanchez de la Cuesta, F. Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers. Eur J Clin Pharmacol 1995 47 : 497 502.
20. De La Cruz JP Mata JM, Sánchez de la Cuesta F. Triflusal vs aspirin on the inhibition of human platelet and vascular cyclooxygenase. Gen Pharmacol 1992 23 : 297 300.
21. Diener HC, Bogousslavsky J, Brass LM, et al. MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomized, double-blind, placebo-controlled trial. Lancet 2004 364 : 331 337.
22. Diez Tejedor E Cerebral infarct (in Spanish). Rev Clin Esp 1996 196 (Suppl 3 1 2.
23. Dutch TIA Trial Study Group. A comparison of two doses aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991 325 : 1261 1266.
24. Farrel B, Godwin J, Richards S, et al. UK-TIA Study Group. United Kingdom transient ischemic attack (UK-TIA) aspirin trial: Final reports. J Neurol Neurosurg Psychiatr 1991 54 : 1044 1054.
25. Fernández de Arriba A, Cavalcanti F, Miralles A, et al. Inhibition of cyclooxygenase-2, expression by 4-trifluoromethyl derivatives of salicylate, triflusal and its deacetylated metabolite, 2-hydroxy-4-trifluoromethyl-benzoic acid. Mol Pharmacol 1999 55 : 753 760.
26. Francia E, Marín A, García-Rafanell J. Triflusal: Antithrombotic agent. Drug Future 1978 3 : 225 228.
27. García LA, Hernández-Díaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiological studies. Br J Clin Pharmacol 2001 52 : 563 571.
28. García-Dorado D, Rami, JV Lamela, A5. Interaction between antiplatelet agents and ACE inhibitors in patients with acute myocardial infarction. Eur Heart J Suppl 1999 1 (Suppl F 24 28.
29. García-Rafanell J, Planas JM, Puig-Parellada P. Comparison of the inhibitory effects of acetylsalicylic acid and triflusal on enzymes related to thrombosis. Arch Int Pharmacodyn Ther 1979 237 : 343 350.
30. García-Rafanell J, Ramis J, Gómez L, Forn J. Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets. Arch Int Pharmacodyn Ther 1986 284 : 155 165.
31. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke. A statement for healthcare professionals from the stroke council of the American Heart Association. Stroke 2001 103 : 163 182.
32. Gomez L, García-Rafanell J, Forn J. Prospective effect of triflusal and acetylsalicylic acid against arachido-nic acid-induced cerebrovascular occlusion in anaesthetized rats. Meth Find Exp Clin Pharmacol 1987 9 : 13 17.
33. González-Correa JA, Arrebola MM, Ureña MI, et al. Effects of triflusal on oxidative stress, prostaglandin production ad nitric oxide pathway in a model of anoxia-reoxygenation in rat brain slices. Brain Res 2004 102 : 148 155.
34. González-Correa JA, Arrebola MM, Ureña MI, et al. P rotective effect of triflusal and its main metabolite HTB in an in vitro model of anoxia-reoxygenation in rat brain slices: Comparison with acetylsalicylic and salicylic acids. Naunyn-Schmiedeberg's Arch Pharmacol 2005 371 : 81 88.
35. Hart RG, Halperin JL, McBride BS, Benavente O, Man-Son-Hing M, Kronmal RA. Aspirin for the primary prevention of stroke and other major vascular events. Meta-analysis and hypotheses. Arch Neurol 2000 57 : 326 332.
36. Hart RG, Halperin JL. Atrial fibrillation and stroke. Concepts and controversies. Stroke 2001 32 : 803 808.
37. Hernandez, M, Fernández de Arriba, A, Merlos M, Fuentes L, Sánchez Crespo M, Nieto ML. Effect of 4-tri-fluoromethyl derivatives of salicylate on nuclear factor κB-dependent transcription in human astrocytoma cells. Br J Pharmacol 2001 132 : 547 555.
38. Heye N, Campos A, Kannuki S, Cervós-Navarro J. Effects of triflusal and acetylsalicylic acid on micro-thrombi formation in experimental brain ischemia. Exp Pathol 1991 41 : 31 36.
39. Heye N, Campos A, Sampaolo S, Cervós-Navarro J. Morphometrical evaluation of triflusal in brain infarction. Acta Neurochim 1993 57 : 53 55.
40. Leonardi-Bee J, Bath PM, Bousser MG, et al. Dipyridamole in Stroke Collaboration (DISC). Dipyridamole for preventing recurrent ischemic stroke and other vascular events: A meta-analysis of individual patient data from randomized controlled trials. Stroke 2005 36 : 162 168.
41. Mant J, Wade D, Winner S. Health care needs assessment: Stroke. In : Stevens, A, Raftery, J, Mant, J, Simpson, S, Eds. Health care need assessment: the epidemiologically based needs assessment reviews. 2nd Edition. Oxford (UK Radclife Medial Press 2004.
42. Matías-Guiu J, Ferro, JM, Aacutelvarez-Sabín, J, et al. TACIP investigators. Comparison of triflusal and aspirin in prevention of vascular events in patients after cerebral infarction: the TACIP Study: A randomized, double-blind multicenter trial. Stroke 2003 34 : 84 848.
43. Mis R, Ramis J, Conte L, Forn J. Binding of a metabolite of triflusal (HTB) to serum protein in rat and man. Eur J Clin Pharmacol 1992 42 : 175 179.
44. Mis R, Ramis J, Conte L, Forn J. In vitro protein binding interaction between a metabolite of triflusal, 2-hydroxy-4-trifluoromethylbenzoic acid and other drugs. J Pharm Pharmacol 1992 44 : 935 937.
45. Patrono C, García LA, Landolfi R, Baigent C. Low dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005 353 : 2373 2383.
46. Perez-Gomez F, Alegria E, Berjon J, et al. NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: A randomized multicenter study. J Am Coll Cardiol 2004 44 : 1557 1566.
47. Ramis J, Mis R, Conte L, Forn J. Rat and human plasma protein binding of the main metabolite of triflusal. Eur J Pharmacol 1990 183 : 1867 1868.
48. Ramis J, Mis R, Forn J, Torrent J, Gorina E, Jané F. Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. Eur J Drug Metab Pharmacokinet 1991 16 : 169 273.
49. Ramis J, Mis R, Forn J. Pharmacokinetics of triflusal and its main metabolite in rats and dogs. Eur J Drug Metab Pharmacokinet 1991 16 : 261 268.
50. Rey A, Martí-Villalta JL. Iatrogenic cerebrovascular disease. Rev Neurol 1995 23 (Suppl 1 S131 S146.
51. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2995 : 352 : 1293 1304.
52. Rimbau V, Forn J. T in vivo. Haemostasis 1982 12 : 385 386.
53. Royal College of Physicians (RCP): The Intercollegiate Working Party. National Clinical Guidelines for Stroke. London (UK) : RCP June 2004.
54. Sánchez de Miguel L, Casado S, Farré J, et al. C omparison of in vitro effects of truflusal and acetylsalicylic acid on nitric oxide syntaxis by human neutrophils. Eur J Pharmacol 1998 343 : 57 65.
55. Sánchez de Miguel L, Jimenez A, Montón M, et al. A 4-trifluoromethyl derivative of salicylate, triflusal, stimulates nitric oxide production by human neutrophils: Role in platelet function. Eur J Clin Invest 2000 30 : 82 817.
56. The SALT Collaborative Group. Swedish aspirin low doses trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular secondary events. Lancet 1991 338 : 1345 1349.
57. Valle M, Barbanoj MJ, Donner A, et al. Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers. Eur J Clin Pharmacol 2005 61 : 103 3.
58. Weinberger J. Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke. Drugs 2005 65 : 461 471.
59. Whitehead S, Cheng G, Hachinski V, Cechetto DF. Interaction between a rat model of cerebral ischemia and β-amyloid toxicity. Stroke 2005 36 : 1782 1789.
60. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation: The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. N Engl J Med 2001 345 : 494 502.